MAP2K7 and pancreatic ductal adenocarcinoma: The combination therapy of the MEK inhibitor trametinib and the multi-kinase inhibitor nintedanib has emerged as a promising solution, targeting the complexities of basal-like mesenchymal pancreatic ductal adenocarcinoma.